Imcyse is pioneering the development of a new class of active, specific immunotherapeutics: ImotopesTM. Imcyse’s new technology platform is based on the discovery of modified synthetic peptides to block the immune processes causing immune-mediated diseases. Imcyse’s ImotopesTM offer the possibility to cure severe chronic diseases for which there is no satisfactory therapeutic alternative. The technology can also prevent the immunogenic responses that weaken the efficiency of chronic therapies.
Our vision is to become a major player in active specific immunotherapy for the curative treatment of autoimmune and allergic diseases.
How does Imcyse technology work ?
Company’s insulin-based Imotope™ IMCY-0098 shows excellent safety profile and promising clinical trends